BioSpectrum Asia - March 2024Add to Favorites

BioSpectrum Asia - March 2024Add to Favorites

انطلق بلا حدود مع Magzter GOLD

اقرأ BioSpectrum Asia بالإضافة إلى 9,000+ المجلات والصحف الأخرى باشتراك واحد فقط  عرض الكتالوج

1 شهر $9.99

1 سنة$99.99 $49.99

$4/ شهر

يحفظ 50%
عجل! العرض ينتهي في 9 Days
(OR)

اشترك فقط في BioSpectrum Asia

سنة واحدة $10.99

يحفظ 7%

شراء هذه القضية $0.99

هدية BioSpectrum Asia

7-Day No Questions Asked Refund7 أيام بدون أسئلة
طلب سياسة الاسترداد

 ⓘ

Digital Subscription.Instant Access.

الاشتراك الرقمي
دخول فوري

Verified Secure Payment

تم التحقق من أنها آمنة
قسط

في هذه القضية

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
We are celebrating International Women's Day this time around by spotlighting women's roles and challenges in life sciences, spanning leadership, clinical trials participation and pay parity issues. Section I of the story highlights remarkable women leading public sector organisations in life sciences in APAC. Section II discusses the persistent issue of pay parity in the sector, while the final section tackles issues related to women in clinical trials. Let's delve deeper.

Ministry of Health in New Zealand inks MoU with of Waikato to build medical school University

The Ministry of Health, government of New Zealand, and the University of Waikato have signed a Memorandum of Understanding (MoU) as a first step towards establishing a new medical school.

Ministry of Health in New Zealand inks MoU with of Waikato to build medical school University

1 min

Australia establishes new task force to guide use of AI in public health system

New South Wales (NSW) Health in Australia has established a new taskforce to inform and guide the use of artificial intelligence (AI) in the public health system.

Australia establishes new task force to guide use of AI in public health system

1 min

NITI Aayog releases report for senior care reforms in India

NITI Aayog has released a position paper titled 'Senior Care Reforms in India: Reimagining the Senior Care Paradigm'.

NITI Aayog releases report for senior care reforms in India

1 min

Eris Lifesciences expands footprint in sterile injectables with acquisition of 51% stake in Swiss Parenterals

India-based Eris Lifesciences has announced the expansion of its sterile injectables footprint through the acquisition of 51 per cent equity stake in Swiss Parenterals for a consideration of Rs 637.5 crore.

Eris Lifesciences expands footprint in sterile injectables with acquisition of 51% stake in Swiss Parenterals

1 min

Biocon Biologics partners with Sandoz Australia for cancer biosimilars

Indian firm Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon, has announced a five-year partnership with Sandoz AG which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million) and biosimilar Bevacizumab (market value of AUD$45 million) in Australia.

Biocon Biologics partners with Sandoz Australia for cancer biosimilars

1 min

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

Samsung Biologics & LegoChem Biosciences team up for ADC development

1 min

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

1 min

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

1 min

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

US FDA approves first medication to treat severe frostbite

1 min

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

10+ mins

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

Championing PAY PARITY

6 mins

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

How pharma is finally researching issues that primarily affect women

8 mins

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

5 mins

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

Why Singapore is Deep Tech Innovation Frontrunner

4 mins

قراءة كل الأخبار من BioSpectrum Asia

BioSpectrum Asia Magazine Description:

الناشرMM Activ Sci-Tech Communication

فئةBusiness

لغةEnglish

تكرارMonthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

  • cancel anytime إلغاء في أي وقت [ لا التزامات ]
  • digital only رقمي فقط